Loading...
Market
Story
Valar Labs Raises $22M Series A for AI-Powered Bladder Cancer Care Tool
May 30, 2024, 04:10 PM
Valar Labs has announced the successful completion of a $22 million Series A funding round, co-led by DCVC and a16z, with participation from Pear VC. The biotech startup has developed an AI-powered diagnostic tool, Vesta, which predicts treatment responses for bladder cancer patients. This tool, based on computational histology, aims to reduce uncertainty in cancer treatment decisions and is already in commercial use for bladder cancer. Valar Labs plans to expand its application to other types of cancer. The technology has been highlighted in a Nature story, and the company aims to translate this tech to clinical settings, potentially saving precious time for patients. There are roughly 2 million new cancer diagnoses annually in the US alone.
View original story
Similar markets
Mayo Clinic • 25%
Cleveland Clinic • 25%
Johns Hopkins Hospital • 25%
MD Anderson Cancer Center • 25%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
Less than 10% adoption • 25%
10% to 25% adoption • 25%
26% to 50% adoption • 25%
More than 50% adoption • 25%
None • 33%
1-5 institutions • 33%
More than 5 institutions • 34%
None • 25%
1-2 • 25%
3-4 • 25%
More than 4 • 25%
Under 25% • 33%
25-50% • 33%
Over 50% • 33%
0-2 new applications • 25%
3-5 new applications • 25%
6-8 new applications • 25%
More than 8 applications • 25%
